Secondary Logo

Institutional members access full text with Ovid®

Human nerve growth factor sensitizes masseter muscle nociceptors in female rats

Svensson, Petera,b; Wang, Mian Weic; Dong, Xu-Dongc; Kumar, Ujendrac; Cairns, Brian E.c,*

doi: 10.1016/j.pain.2009.12.009

Injection of nerve growth factor (NGF) into the masseter muscle is not painful but does induce a localized, quick onset (˜1 h) and long-lasting mechanical sensitization in healthy human subjects. We tested the hypothesis that human NGF mechanically sensitizes masseter muscle nociceptors by increasing the sensitivity of peripheral N-methyl-d-aspartate (NMDA) receptors. Co-expression of the NR2B subunit of the NMDA receptor with P75 and TrkA NGF receptors by trigeminal ganglion neurons that innervate the masseter muscle was investigated immunohistochemically. Nociceptor activity was recorded extracellularly from the trigeminal ganglion of anaesthetized female rats. Nociceptor mechanical threshold was assessed before and every 30 min for 3 h after injection of human NGF (25 μg/ml, 10 μl, n = 12), and in subsequent experiments NGF with TrkA (n = 12) or P75 (n = 11) receptor antibodies. Glutamate (1 M, 10 μl) was injected at the end of each experiment. Approximately 85% of NR2B positive masseter ganglion neurons co-expressed P75 or TrkA receptors, suggesting the potential for interaction. When compared with the vehicle control, it was found that injection of NGF into the masseter muscle did not evoke significant nociceptor discharge but did significantly reduce nociceptor mechanical threshold (˜30%). There was no effect of NGF on glutamate-evoked nociceptor discharge or glutamate-induced mechanical sensitization. Additional experiments indicated that NGF-induced mechanical sensitization could be partially attenuated with TrkA receptor antibodies, but not P75 receptor antibodies. These findings indicate that human NGF-induced sensitization of masseter nociceptors results, in part, from the activation of TrkA receptors, but does not appear to be mediated through enhanced peripheral NMDA receptor activity.

aDepartment of Clinical Oral Physiology, School of Dentistry, Faculty of Health Sciences, University of Aarhus, DK-8000 Aarhus C, Denmark

bDepartment of Oral and Maxillofacial Surgery, Aarhus University Hospital, DK-8000 Aarhus C, Denmark

cFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada V6T 1Z3

*Corresponding author. Address: Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, British Columbia, Canada V6T 1Z3. Tel.: +1 604 822 7715; fax: +1 604 822 3035.


Submitted June 26, 2009; revised December 9, 2009; accepted December 15, 2009.

© 2010 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website